PP_1170x120_10-25-21

Repatha

Amgen’s Repatha OK’d to help prevent heart attack, stroke

Amgen’s Repatha OK’d to help prevent heart attack, stroke

THOUSAND OAKS, Calif. — After a priority review of its supplemental Biologics License Application, Amgen has gained approval from the Food and Drug Administration for the cardiovascular drug Repatha. Amgen said Repatha (evolocumab 140 mg/ml injection) is the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.

Adheris Health